Semantic Scholar uses AI to extract papers important to this topic.
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and… Expand 4503Background: ERDA is an FGFR inhibitor with activity in pts with mUC and FGFRalt. FGFRalt occur in 10-20% of mUC and are… Expand 411Background: Although immune checkpoint inhibitors (ICI) have improved outcomes in some pts with platinum-resistant mUC, many… Expand Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound… Expand Fibroblast growth factor receptor (FGFR) genetic alterations are frequently observed in cancer, suggesting that FGFR inhibition… Expand PURPOSE
JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. This first… Expand Purpose: Oncogenic fusions consisting of fibroblast growth factor receptor (FGFR) and TACC are present in a subgroup of… Expand BackgroundWe examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth… Expand 2501 Background: JNJ-42756493 is an orally bioavailable FGFR 1, 2, 3 and 4 inhibitor with nanomolar antitumor activity in cell… Expand Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA
Background: JNJ-42756493 is an FGFR 1, 2, 3, and 4… Expand